BCL2 and breast cancer: The therapeutic significance of PRKACA expression in cancer had previously been suggested by a breast cancer study, which showed that PRKACA mediates resistance to anti-HER2 therapy in breast cancer cell lines via inactivation of BAD and Bcl2-associated death promoter [17].